3D InSight™ Liver Microtissues

 InSphero offers advanced, pre-validated 3D liver models engineered to help you assess toxicity risk earlier in the drug discovery process, and screen drugs for metabolic diseases of the liver, such as fibrosis. 

 


 

De-risk with Greater Confidence

3D InSight™ Liver Microtissues are standardized 3D liver models, produced using primary hepatocytes and non-parenchymal liver cells. These advanced liver models accurately reflect the structure and biology of in vivo liver, delivering greater confidence in decision-making based on in vitro cell-based assays for liver injury and drug efficacy testing.

Explore key mechanisms of healthy and diseased liver function

Our liver microtissues are comprised of primary human or animal hepatocytes and non-parenchymal liver cell types, such as Kupffer cells and liver endothelial cells, resulting in native-tissue-like functionality. They exhibit albumin secretion, polarized cellular organization, robust cytochrome P450 activity, high mitochondrial function, and bile-acid transport to bile canaliculi. This long-lived model improves sensitivity for DILI prediction by enabling long-term drug exposure and by including a physiologically relevant ratio of primary hepatocytes to non-parenchymal cells.

 Power_of_3D_InSight_Liver_Microtissues


  AZ Gen Paper thumb 01

Improve sensitivity for DILI prediction by employing long-term drug exposure

Guaranteed viability for 28 days in most of our liver models allows highly reproducible assessment of both chronic and short-term drug exposure without the use of animals. Learn how you can detect DILI earlier and read the Arch Toxicol Paper

assay plate and media

Ensure reproducibility and continuity in longitudinal and multi-site studies

Order standardized, pre-qualified liver models, certified for liver toxicology applications, such as DILI prediction, that are available for delivery direct to your lab when you're ready to start experiments. Check our production schedule

 


Human and Animal-derived Liver Microtissues


Radina Kostadinova 01"Making primary hepatocyte-derived liver microtissues containing the appropriate number of non-parenchymal cells is complicated. In a European consortium, which performed a ring trial with 3D liver models, multiple labs failed to produce liver models themselves despite all using the same protocol and donor cells. When using InSphero’s assay-ready 3D InSight™ Microtissues, you avoid high upfront costs and frustrations, so you can focus on the most important part: generating reproducible data with a robust 3D model you can rely on."

RADINA KOSTADINOVA, PHD
3D InSight™ Liver Microtissue Product Manager


Certified Applications


Services

DILI Prediction
Tier 1: Short-term (max. 7 days)
Tier 2: Long-term (14 days)
Translational Toxicity



Mechanistic Assays
Mitochondrial Toxicity
Inflammation-mediated Toxicity
CYP-mediated Toxicity
Cholestasis
Drug-induced Steatosis
Apoptosis
Omics Profiling

 

 




In Vitro Toxicology
DILI Evaluation
14 Day Hepatotoxicity
Cross-species Hepatotoxicity
Custom Mechanistic & Investigative Studies
Mitochondrial Toxicity

 

 

Debating whether to make or buy your liver microtissues? Read this first.

3D select technology white paper

InSphero 3D InSight™ Liver Microtissues are next-generation 3D models for DILI and investigative toxicity testing.  Using the 3D Select™ Process, we ensure only the most viable hepatocytes incorporate into our microtissues, improving viability and organotypic morphology.  When compared head-to-head to conventional production methods, there is no comparison. See the results in this White Paper:


Perfecting cellular self-assembly: Prerequisites for industrial-scale production of 3D microtissues for drug discovery and development.

 

Company video

company-video-inspheor